Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04148001 · ClinicalTrials.gov registry record
Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients
A clinical trial of Homozygous Familial Hypercholesterolemia (HoFH), sponsored by REGENXBIO.
- Completed
- Registry status
- 4
- Enrollment target
- 1
- Study location
NCT04148001: Completed study of Homozygous Familial Hypercholesterolemia (HoFH), sponsored by REGENXBIO.
NCT04148001 is a study of Homozygous Familial Hypercholesterolemia (HoFH) that has completed, run by REGENXBIO. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04148001, a study of Homozygous Familial Hypercholesterolemia (HoFH), has completed, sponsored by REGENXBIO.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to help identify patients with HoFH due to mutations in the LDLR as confirmed by genotyping.
Primary Outcome
The number of participants who have HoFH due to mutations in the LDLR (low density lipoprotein receptor) gene as confirmed by genetic testing.
Conditions Studied
Study Locations (1)
Florida
- Excel Medical Clinical Trials, LLC - Boca Raton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2020-04-08 |
What the finished NCT04148001 record still lists
NCT04148001 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 1 condition, with Homozygous Familial Hypercholesterolemia (HoFH) appearing as the primary indexed condition, and to 0 interventions.
NCT04148001 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04148001 about?
NCT04148001 is a clinical study titled "Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients". This study is designed to help identify patients with HoFH due to mutations in the LDLR as confirmed by genotyping.
What is the current status of trial NCT04148001?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2019-12-04. Estimated completion is 2020-04-08.
What conditions does trial NCT04148001 study?
This clinical trial studies the following conditions: Homozygous Familial Hypercholesterolemia (HoFH).
Who is sponsoring clinical trial NCT04148001?
This trial is sponsored by REGENXBIO, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04148001 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homozygous Familial Hypercholesterolemia (HoFH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI